Stocks · News reference
Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics, today closed its previously
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Aptevo Therapeutics (NASDAQ:APVO) reported quarterly losses of $(5.31) per share which beat the analyst consensus estimate of $(6.16) by 13.8 percent. This is a 96.49 percent increase over losses of $(151.20) per share
Read original at benzingaFiled: 2026-08-14 AccNo: 0001193125-26-350537 Size: 210 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgar